alcoholic%20liver%20disease
ALCOHOLIC LIVER DISEASE
Alcoholic liver disease diagnosis is suggested by an established history of habitual alcohol intake of sufficient length and intensity.
Toxic daily threshold of alcohol consumption is 40-80 g for males and 20-40 g for females for 10-12 years.
Signs of alcohol abuse and hepatic injury include malnutrition and muscle wasting, cutaneous telangiectasia, palmar erythema, finger clubbing, Dupuytren's contracture, peripheral neuropathy, parotid gland enlargement and signs of gynecomastia and hypogonadism may also be present.

Lifestyle Modification

Abstinence from Alcohol

  • Cornerstone of long-term management of alcoholic liver disease (ALD)
  • Patient should be strongly encouraged to abstain or greatly reduce alcohol intake, particularly obese or chronic hepatitis C virus patients
  • Educate the patient regarding the nature of the disease and the benefit of discontinuing alcohol intake
    • Abstinence or marked reduction in alcohol intake has been shown to improve histology and/or survival in all stages of ALD
      • Abstinence can cause total resolution of alcoholic steatosis
  • Assistance should be given to the patient to help them change their behavior
    • Alcohol relapse may be effectively reduced by motivational interventions, eg cognitive behavioral therapy
  • Patient may require consultation with a psychiatrist or addiction specialist
  • Naltrexone or Acamprosate may help decrease risk of relapse in patients with alcohol abuse or dependence who have achieved abstinence and have no advanced ALD
  • Baclofen is used in patients with moderate alcohol withdrawal symptoms and to prevent alcohol relapse in patients with advanced ALD
  • Benzodiazepines are used in patients with severe alcohol withdrawal syndrome and ALD

Other Lifestyle Modifications

Smoking Cessation

  • Smoking may increase rate of progression of fibrosis in ALD
  • Patients should be encouraged to stop smoking

Obese Patients

  • Body mass index (BMI) has been shown to be an independent risk factor for ALD development
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Hepatology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 6 days ago

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

6 days ago
Blood pressure (BP) in children is influenced by early-life exposure to several chemicals, built environment and meteorological factors, suggests a study.
6 days ago
Short sleep duration is associated with an increased risk of myocardial infarction (MI), according to prospective observational and Mendelian randomization (MR) analyses.
Tristan Manalac, 6 days ago
The addition of ezetimibe improves statin treatment in acute coronary syndrome (ACS) patients with dyslipidaemia and low eicosapentaenoic acid-to-arachidonic acid (EPA/AA) ratio, resulting in a lowered risk of cardiovascular events compared to monotherapy, according to a study presented at the recently concluded 2019 Congress of the European Society of Cardiology (ESC 2019) held in Paris, France.